Detection of Intra-Tumor Self Antigen Recognition during Melanoma Tumor Progression in Mice Using Advanced Multimode Confocal/Two Photon Microscope by Schaer, David A. et al.
Detection of Intra-Tumor Self Antigen Recognition
during Melanoma Tumor Progression in Mice Using
Advanced Multimode Confocal/Two Photon Microscope
David A. Schaer
1., Yongbiao Li
3., Taha Merghoub
1,2, Gabrielle A. Rizzuto
1,4, Amos Shemesh
1, Adam D.
Cohen
2¤, Yanyun Li
1, Francesca Avogadri
1, Ricardo Toledo-Crow
3, Alan N. Houghton
1,2,4", Jedd D.
Wolchok
1,2,4*
"
1Swim Across America Laboratory, Immunology Program, Sloan-Kettering Institute for Cancer Research, New York, New York, United States of America, 2Department of
Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America, 3Research Engineering Lab, Sloan-Kettering Institute for Cancer
Research, New York, New York, United States of America, 4Weill Medical College of Cornell University, New York, New York, United States of America
Abstract
Determining how tumor immunity is regulated requires understanding the extent to which the anti-tumor immune
response ‘‘functions’’ in vivo without therapeutic intervention. To better understand this question, we developed advanced
multimodal reflectance confocal/two photon fluorescence intra-vital imaging techniques to use in combination with
traditional ex vivo analysis of tumor specific T cells. By transferring small numbers of melanoma-specific CD8+ T cells (Pmel-
1), in an attempt to mimic physiologic conditions, we found that B16 tumor growth alone was sufficient to induce naive
Pmel-1 T cell proliferation and acquisition of effector phenotype. Tumor -primed Pmel-1 T cells, are capable of killing target
cells in the periphery and secrete IFNc, but are unable to mediate tumor regression. Within the tumor, Pmel-1 T cells have
highly confined mobility, displaying long term interactions with tumor cells. In contrast, adoptively transferred non tumor-
specific OT-I T cells show neither confined mobility, nor long term interaction with B16 tumor cells, suggesting that intra-
tumor recognition of cognate self antigen by Pmel-1 T cells occurs during tumor growth. Together, these data indicate that
lack of anti-tumor efficacy is not solely due to ignorance of self antigen in the tumor microenvironment but rather to active
immunosuppressive influences preventing a protective immune response.
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Introduction
It is known that the immune system can generate responses to
antigens expressed by cancer cells [1]. However, barriers remain
at the level of the tumor, and possibly in the secondary lymphoid
organs, which prevent effective cancer immunity [2,3]. Determin-
ing the exact nature of these barriers is of the utmost importance in
development of effective tumor immunotherapy.
During malignant transformation and progression, rounds of
immuno-editing occur, resulting in a tumor with the ability to
e v a d ei m m u n ed e s t r u c t i o n[ 4 ] .W h i l et h ec o n c e p to fi m m u n o -
editing has become accepted, the exact escape mechanisms used
by various cancers remain a source of debate. A growing body
of evidence suggests active inhibition of T cell effector functions
by tumor cells and/or cells of the tumor stroma [5,6,7].
However, passive processes, such as immune ignorance or
deletion of highly reactive ‘‘self’’ T cell clones during central
tolerance induction may also prevent tumor eradication [8].
The processes that avert autoimmunity may also prevent the
generation of effective anti-tumor immunity [9]. While these
various mechanisms have different mediators and temporal
separations, they may not be mutually exclusive. It is possible
that multiple processes cooperate to prevent effective tumor
immunity.
Technological advances in imaging permit us to examine,
through the use of two photon laser scanning microscopy
(TPLSM), the anti-tumor immune response in real time, in vivo.
TPLSM has already improved our understanding of in vivo
priming of the immune response to foreign antigens, by
examining T cell interactions in secondary lymphoid organs
[10,11]. In addition, recent research has examined effector phase
anti-tumor responses to tumors expressing the foreign antigen
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21214OVA (hen ovalbumin) [12,13,14]. However, studies have yet to
investigate the immune response to a self antigen in a progressive
syngeneic tumor model. The use of artificial foreign antigen
tumor models, supra-physiologic numbers of transferred T cells
and explanted tumor imaging may not be representative of
natural conditions. Although TPLSM imaging is inherently
invasive, intra-vital techniques which preserve the integrity of
the tumor microenvironment can lessen the impact of imaging on
the biology. These include tracking of T cell responses against
natural self antigens in a relatively un-manipulated manner using
low numbers of precursors which more closely match endogenous
populations.
In this study, we attempted to visualize the anti-tumor immune
response in settings that more closely mimic physiological
conditions, through the development of a novel high speed
TPLSM with the added capacity to capture backscattered or
reflected light. Combining intra-vital imaging techniques with ex
vivo analysis, we tracked small numbers of un-manipulated self
antigen tumor-specific CD8+ T cells both temporally and
spatially. Naı ¨ve B16 tumor specific Pmel-1 CD8+ T cells
transferred into tumor-bearing mice proliferate, acquire an
activated effector phenotype, and traffic to the tumor. Within
the tumor, Pmel-1 T cells have confined mobility, displaying long
term interactions with tumor cells. In contrast, co-transferred non
tumor-specific OT-I effector T cells showed neither confined
mobility nor long term interactions with B16 tumor cells unless
B16 was engineered to express OVA. These data support intra-
tumor recognition of cognate self antigen by Pmel-1 T cells
demonstrating that despite tumor progression, intra-tumor
ignorance of self antigen does not act as a barrier to tumor
immunity.
Materials and Methods
Ethics Statement
All mouse procedures were performed in accordance with
institutional protocol guidelines at Memorial-Sloan Kettering
Cancer Center (MSKCC) and were maintained according to
NIH Animal Care guidelines, under a protocol 96-04-017
approved by the MSKCC Institutional Animal Care Committee.
Mice and tumors
C57B/6J, C57B/6J
THY1.1, GFP and CFP mice were acquired
from Jackson laboratories. Pmel-1 mice, were a gift from Nicolas
Restifo (NCI, MD. The B16F10 mouse melanoma cell line was
originally obtained from I. Fidler (M.D. Anderson Cancer Center,
Houston, TX) (B16). For imaging experiments B16 was stably
transfected by electroporation with a pcDNA3.1 vector (Invitro-
gen) encoding EYFP (Clonetech) (YFP-B16). Cells were cultured in
RPMI 1640 medium containing 7.5% FBS. Growth medium for
YFP-B16 was supplemented with 0.5 mg/ml G418.
Flow cytometry and Antibodies
Tissue was homogenized through 40 mm strainers to produce
single cell suspensions for FACS analysis. Cell suspensions were
labeled using the following BD antibodies CD3, CD4, CD8
CD11b, CD44, CD45, CD62L, NK1.1, GR-1, Foxp3
(Ebioscience), CFSE (Invitirogen). Samples were acquired on
either 5 channel or 12 channel flow cytometers (BD).
Adoptive transfer of CD8+ T cells
CD8+ T cells were prepared for adoptive transfer by isolation
of spleen and LNs from donor mice. Tissue was homogenized
and CD8+ T cells were positively selected using magnetic
antibody cell separation (Miltenyi). CD8+ T cells were resus-
pended in PBS and transferred to recipient mice through tail vein
injection.
In vivo killing assay
Congenic CD45.1 splenocyte targets were loaded with 20 mg/ml
of either relevant (gp100) or irrelevant (OVA) peptides in media for
1 hour at 37u and then labeled either a high (5 mM) or low (0.5 mM)
level of CFSE, respectively. 5610
5 of each target cell was then
transferred by tail vein injection to recipient mice at a 1:1 ratio.
Measuring the ratio of gp100 loaded targets to OVA loaded targets
isolated from the CD45.1 gate in the control mice which did not
receive tumor provides the baseline level of gp100 target cells which
remain after transfer.
Intravital Imaging
YFP-B16 tumors were injected in the left flank of mice upstream
of the inguinal LN. 6210 days post AT (days 9213 of tumor
growth), 2 mice were imaged per day to detect the peak of Pmel-1
T cell tumor infiltration per experiment, (usually 728 days post
AT, day 10211 of tumor growth). Multiple time points were
imaged in order to find the peak point of infiltration and
compensate for variability associated with each tumor injections,
priming response and 3 dimensional tumor structures. Mice are
anesthetized with 1.5% isoflurane delivered by 1 L/hour O2 on a
heated platform maintained at 37uC. Surgery is performed to open
up a skin flap to expose the tumor and inguinal LN while
maintaining vasculature integrity. The tumor and TDLN are then
isolated under nylon washer mounted coverslips, with PBS and
visualized with a heated (37uC) objective. Temperature of isolated
tissues is checked with a thermal probe to ensure it is maintained at
37uC. Time lapse images are acquired with a Z-depth on the
average of 1002150 mm with 3 mm between steps, starting at +/2
10 mm from the top edge of the tumor. Mosaic images are taken
with 50 mm overlaps between adjacent regions. The video capture
rate of over 20fps enables 6:1 frame averaging with a sample area
that includes up to 9 adjacent 270 mm6270 mm6100 mm volumes
to produce a mosaic image every 80–120 seconds. Time lapse
images vary in length from 60–120 min. To control for tissue
viability after surgery and as a baseline for Pmel-1 T cell mobility,
inguinal TDLNs were imaged alongside tumors in each experi-
ment.
Image Analysis
Mosaic Images compiled together using custom MatLab
program and imported into Volocity. Movies were generated to
determine if regions imaged displayed viable cell movement
(Blood flow, YFP ghosts) beforeTc e l lt r a c k i n gw a sp e r f o r m e d
on individual regions. Images were corrected for contrast with
36363 pixel noise filtering to remove background signal where
necessary. Individual T cell tracks were calculated using
Volocity automatic object acquisition and tracking modules.
Each track was verified for algorithmic errors. Image drift was
calculated by tracking 3–6 tumor landmarks per image, per time
point during time lapse. The average movement of the
landmarks was removed from all calculated trajectory and
velocity measurements accordingly. Intra-tumor T cells posi-
tions were calculated by producing a high digital threshold map
of the tumor images were analyzed using and custom-developed
Matlab code. Mean distance from the Central Point of
Movement (Mean DCPM) was calculated using the centroid
positions of each cell tracked for over 10 time points according
to this equation:
Intra-Tumor Imaging of Self Antigen Recognition
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21214CM(x,y,z)~
X N
i~1
P(xi)=N,
X N
i~1
P(yi)=N,
X N
i~1
P(zi)=N
()
MDCM~
X N
i~1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(P(xi){CM(x))
2z(P(yi){CM(y))
2z(P(zi){CM(z))
2
q ,
N
P(x), P(y) and P(z) are the Cartesian coordinates of individual
observations. N is the length of observations. CM is the Cartesian
coordinate of the Central Point of Movement. Mean DCPM is the
mean distance of individual observation from CM. Statistical
comparisons of Pmel-1 vs OT-I were done in Graph pad Prism 5
using a student T test. Statistical comparison of the raw mean
DCPM was done using Kruskal-Wallis test with pair wise
comparisons. Mean DCPM were then converted to mm Log10
to enable population frequency distribution calculations, in order
to determine the mode for each population. Due to high density of
YFP-B16 tumor mass, images and movies are displayed in 3D
volumes instead of 2D projections to enable more accurate
presentation of cell location respective to other.
Results
Peak effector and regulatory immune cell tumor
infiltration occurs 8–10 days after B16 tumor challenge
In order to investigate the intra-tumor dynamics of self antigen
responses during the peak of the anti-tumor immune response, we
first determined the precise activation kinetics of the anti-B16
immune response. Prior research, by our group and others, has
been limited to examining tumor infiltrating lymphocytes during
late stages of tumor growth (greater than 14 days after tumor
challenge), or during immunotherapy [2,15]. Therefore, we began
our analysis 2 days after tumor challenge, using tumors injected
subcutaneously in growth factor reduced Matrigel, to develop a
more complete understanding of the early tumor microenviron-
ment [16]. Using this method, we determined that peak immune
infiltration (as a percentage of total cells) was between days 8–10 of
tumor growth (Fig 1A, B). At the peak (day 8–10), there were
relatively equal percentages of CD8+ and CD4+ T cells in the
tumor (,5%). At the same time, putative MDSCs (CD11b+,
GR1+ of the macrophage lineage F4/80+) constituted ,12% of
the total tumor burden. A more detailed analysis of the leukocyte/
myeloid infiltrate was accomplished after density gradient
centrifugation of the tumors (Fig. 1B). ,40% of the CD4+ cells
present in the tumor were Foxp3+ Tregs, demonstrating a
selective recruitment of inhibitory cells to the tumor as a portion
of total leukocytes compared to the TDLN. This suggests that the
effector response is activated with the same kinetics as a putative
inhibitory response. As tumors progressed, B16 cells composed the
majority of the tumor (,80–90% of all cells after ,15–18+ days)
and the levels of all infiltrating immune cells decreased (data not
shown).
Determining activation kinetics of T cell responses to B16
self antigen gp100
Subsequently, the rate at which B16-specific CD8+ T cells from
the Pmel-1 mouse are naturally primed and traffic to the tumor
was investigated. CD8+ T cells in this mouse express a naturally
selected TCR and are reactive to the melanoma self antigen
gp100, but are unable to reject B16 tumors without other immune
manipulation [17,18,19]. This suggests that at the steady state,
Pmel-1 T cells are either susceptible to tumor mediated inhibition
or the strength of their effector function is not sufficient to provide
tumor killing. We began by determining the Pmel-1 T cell
response kinetics to B16 growth. Naı ¨ve Pmel-1 T cells proliferated
and acquired effector phenotypes with similar kinetics when
2610
6 cells were adoptively transferred (AT) into mice bearing 0,
3, 6 or 9 day old B16 tumors (example of this data is shown in
Fig. 2A,B). Naı ¨ve (CD62L
High,CD44
Low,CFSE
High) Pmel-1 T cells
infiltrated the tumor-draining lymph node (TDLN) and spleen
within 24 hours (,10,000 cells in TDLN & 100,000 in spleen),
while few cells were seen in the tumor (,,500 cells) (Fig. 2A,B).
Initial activation and proliferation of the Pmel-1 T cells required
three days as measured by up-regulation of CD44 and dilution of
CFSE. After 5 days, activated Pmel-1 T cells (CD62
Low,CD44
High,
CFSE
low) began infiltrating the tumor with infiltration peaking 7
days post AT and over 90% of Pmel-1 T cells displaying an
activated phenotype (Fig. 2A). Similar to the activation kinetics,
Pmel-1 T cell tumor infiltration was comparable after transfer into
mice 3, 6, and 9 days after tumor challenge (Sup Fig. S1A). While
gp100 is expressed by normal melanocytes in C57BL/6 mice,
priming of Pmel-1 T cells is tumor growth-dependent as they do
not proliferate nor become activated in the absence of or during
mock (Matrigel alone)tumor challenge (Sup Fig. S1B).
The transfer of supra-physiologic numbers of T cell precursors
has been shown to alter responses due to competition for antigen
by T cells [18,20], so we compared AT of 2610
6,1 610
6,o r
3610
5 Pmel-1 T cells into mice bearing 3-day old tumors. In
agreement with previous studies, our data demonstrated that lower
numbers of transferred Pmel-1 T cells results in greater
proliferation and activation (Fig. 2C). Transfer of 3610
5 cells
was chosen as the lower limit as it enabled detection of sufficient
numbers of cells during intra-vital imaging, while remaining close
to the optimal number of Pmel-1 T cells as determined in our
previous adoptive cell therapy experiments [18].
Naı ¨ve Pmel-1 T cells primed by tumor growth produce
competent CTL effector T cells
Since naive Pmel-1 T cells proliferate and acquire an effector
phenotype solely in the presence of B16 tumors, it suggests that
there is no systematic defect in physiological antigen recognition.
However, we could not exclude the possibility that priming is
somehow defective. This has been observed in CT44 tumors
expressing influenza HA antigen where tumor specific CTL
primed in the presence of antigen specific Tregs appear fully
activated in the TDLN, but have reduced effector capacity in the
periphery, failing to cause tumor regression [21,22]. Therefore, we
assessed the quality of the Pmel-1 effector response by examining
cytokine production and killing of cognate targets. Starting as early
as 4 days after tumor challenge, we found that ,5% of Pmel-1 T
cells have detectable levels of IFNc in the TDLN (Fig. 3A). By
seven days after tumor challenge, a large percentage of tumor
infiltrating Pmel-1 T cells (,17%) are IFNc positive, increasing to
over 30% by day 14. This data is in agreement with the activation
kinetics described above, as tumor infiltrating Pmel-1 demonstrat-
ed the largest percentage of effector cells compared to TDLN and
spleen.
Although physiologic priming of Pmel-1 T cells is sufficient to
produce effector cytokines, tumors grow progressively, suggesting
that Pmel-1 T cells are unable to kill inside the tumor. However, if
immune inhibition only occurs in the tumor, it is possible that
Pmel-1 T cells could display lytic ability in the periphery. To
establish if tumor-primed Pmel-1 T cells have anti-gp100 lytic
potential, we performed an in vivo killing assay. Target cells, loaded
Intra-Tumor Imaging of Self Antigen Recognition
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were injected six days post Pmel-1 AT to coincide with the peak of
Pmel-1 T cell priming. Examining changes in gp100/OVA target
ratio shows that Pmel-1 T cells have lytic ability in the periphery
(Fig. 3B). Even though Pmel-1 effector T cells represent only ,0.1
or 0.5% of the spleen at day 7 based on transfers of 3610
5 or
Figure 1. Effector and inhibitory immune cell infiltrates in B16 tumors with parallel kinetics. 2.56105 B16 tumor cells were suspended in
matrigel and inoculated into WT C57B/6 mice. Tumors and TDLN were isolated and assessed for immune cell percentages to determine the peak of
tumor infiltration time. (A) Representative FACS plots show CD4+, CD8+ and MDSC (GR1+/CD11b+) percentages of total tumor cells isolated from
individual 8 day old B16 tumors. Graphs show mean (+/2SEM) infiltration for CD8+ (4.4%, N=22) CD4+ (5%, N=15) and GR1+ CD11b+ (12%, N=9) in
day8–10B16tumors.(B)FACSplotsofleukocytemarkerstaining,postdensitygradientcentrifugationoftotaltumorandTDLNs.NK1.1,CD8, andCD11b
plots were gated on live cell fractions (7AAD-). Parent gate for MDSCs (CD11b+GR1+) plot is CD3-NK1.1-. Parent gate for CD4+/CD8+ T cells is CD3+NK1.
N=4 and15forday 8 andday 10,respectively. Piecharts showdistribution ofcell types asa percentageoftheleukocytecompartmentinsidethetumor.
doi:10.1371/journal.pone.0021214.g001
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6 naive cells, we were able to detect ,17% and 21%
specific lysis of gp100 loaded targets, respectively (Fig. 3B).
Together, the fact that Pmel-1 T cells can recall IFNc and display
detectable lytic capacity implies that the priming received in the
TDLN is not inherently defective. This would suggest that the
response to self antigen may be regulated in the tumor.
Unique dual mode reflectance confocal and two-photon
microscope permits video-rate imaging of fluorescence-
labeled and un-labeled cells
Having established the early priming kinetics of the immune
system against B16 tumor growth, we next developed a system to
investigate intra-tumor dynamics of the response. To enable intra-
vital imaging in conditions that most closely mimicked the
physiologic environment, we engineered a novel high speed dual
mode, reflectance confocal and TPLSM (Fig. 4A). Combining a
high frame rate (,22fps) with a programmable stage, our
microscope permits imaging of multiple adjacent regions contin-
uously. This important feature enhanced our ability to track in-vivo
activated Pmel-1 T cells as they represented only ,,0.01% of the
total tumor, allowing us to observe larger imaging volumes
producing a more representative sample of the tumor infiltrating
Pmel-1 T cells.
Our design achieves high scanning rates with no beam retrace
exposure; resulting in short laser dwell times (,120 ns) and lower
levels of phototoxicity. This is achieved by combining a 32–facet
polygon mirror spinning at approximately 22,000 RPM for the
fast, horizontal (X-) scanning with galvanometer generated vertical
(Y-) scanning (Fig. 4A & Sup Fig. S2 for detailed description). The
unidirectional rotation of the polygon mirror eliminates retrace
laser exposure of the sample and the fast spin rate allows this
scanner to reach up to 22 fps.
Additionally, we included the capacity of collecting backscat-
tered infrared laser light reflected from tissue samples, along with
four fluorescence detector channels. Reflectance imaging provides
much needed context to the ‘‘black void’’ usually seen in other two
photon images, producing a contrast picture of the tissue being
illuminated (Fig. 4B, C). While commercial systems discard the
reflected infrared light, in our system it retraces the beam path,
and is collected with a confocal detector (Fig. 4A, Sup Fig. S2).
This enables visualization of extracellular matrix collagen fibers
(similar to the 2
nd harmonic optical signals generated by collagen
fibers [23]) along with unlabeled cells (Fig. 4B, C). Reflectance also
permits the analysis of T cell migration in the blood vessels as well
and identification of flow rates of red blood cell (Fig. 4C, Movie
S1). This alleviates the need for marker dyes to measure the
location of vasculature, or second harmonic generation to visualize
collagen fibers, freeing up fluorescent channels for biological
measurements.
Development of B16 Intra-Vital Imaging Model
In order to assay if Pmel-1 T cells function inside progressing
B16 tumors, Pmel-1 transgenic mice were crossed with transgenic
mice expressing green fluorescent or cyan fluorescent protein
(referred to as GFP-Pmel-1 & CFP-Pmel-1, respectively) and B16
was transfected with enhanced yellow fluorescent protein (B16-
YFP). Additionally, as a control, non specific OT-I T cells were
crossed to GFP mice, and B16 which expresses OVA (MO4) was
transfected with YFP (MO4-YFP). Importantly, activation and
tumor infiltration of transferred double transgenic fluorescent
Pmel-1 cells was comparable to non-fluorescent single transgenic
pmel-1 cells (data not shown). Similarly, B16-YFP chosen for
experiments grew with comparable kinetics and had similar
immune infiltration to the parental B16, remaining a target for
gp100 specific lysis by activated Pmel-1 T cells (Supplemental Fig.
S3A, B).
Pmel-1 T cells engage in long term interactions with
tumor cells demonstrating intra-tumor self antigen
recognition
Our evidence thus far suggests that Pmel-1 effector phase
function is inhibited after tumor entry. Aside from active inhibition
by Tregs, it is possible that the tumor micro-environment is caustic
to effector T cell function through tryptophan and arginine
metabolites or hypoxic conditions [24,25]. Therefore, to deter-
mine the extent to which Pmel-1 T cells were functional, we
assessed their mobility after tumor infiltration, comparing it to co-
transferred non specific OT-I T cells in the same tumor. Because
the overall 3D tumor structure, cytokine milieu, and/or density of
collagen may affect T cell migratory patterns [26,27], this method
allows us to separate the contribution of antigen specificity from
general non-specific effects of the tumor environment. Equivalent
numbers of GFP-OT-I T cells and CFP-Pmel-1 T cells were AT
into mice bearing 3 day B16-YFP tumors. OT-I T cells were
primed in-vivo with OVA loaded DCs which were transferred 1
day later. DCs were injected into the contralateral foot pad to
prevent possible interference with Pmel-1 priming in the TDLNs.
This method resulted in the concurrent recruitment at the peak of
tumor immune infiltration of similar numbers of activated GFP-
OT-I T cells and activated Pmel-1 T cells to the tumor (Fig. 5A).
Tumor regions were then chosen for imaging based on both the
presence of Pmel-1 and OT-IT cells, vasculature with circulating
cells and evidence of active movement by unlabeled stromal cells
(detected as YFP ghosts, Movie S2). Consistent with the
distribution of CD8 T cells and other leukocytes, the activated
Pmel-1 T cells were found in proximity to tumor neo-vasculature
(,60–100 mm) and not more deeply imbedded in the tumor mass
(Sup Fig. S4 A,B).
Initial observations showed that Pmel-1 T cells were alive,
displaying highly confined mobility, and engaging in long term
interactions with tumor cells (Fig. 5A, Movie S3, S4, S5; Images
and movies are displayed in 3D volumes instead of 2D
projections to enable accurate presentation of cell location
respective to other). Notably, tumor specific Pmel-1 T cell
mobility was dramatically different from the non-specific OT-I T
cells which displayed no obvious long term interactions with
tumor cells (Fig. 5A, Movie S4, S5). Tumor specific Pmel-1 T
cells had an average mean velocity less than half the speed of non
Figure 2. Naı ¨ve B16 specific Pmel-1 T cells are primed by tumor growth and infiltrate tumors after adoptive transfer into tumor
bearing mice. 2.5610
5 B16 tumor cells were inoculated in matrigel into WT C57B/6 mice. Naive CFSE labeled Thy 1.1+ CD8+ Pmel-1 T cells were AT
either 6 days (A, B) or 3 days (C) after tumor challenge. Spleens, TDLNs and tumors were isolated from 3 mice every 24–48 hours after AT for up to 11
days post transfer and analyzed for Pmel-1 T cell infiltration and activation (A) LEFT, representative SSC/Thy 1.1 FACS plots from 7 days post AT of
2610
6 naı ¨ve Pmel-1 T cells show percentages of infiltrating Thy 1.1+ Pmel-1 T cells. RIGHT panels shows CD44/CFSE, CD62L/CFSE on noted days post
AT. Gates show representative percentages of activated (CD44
High/CFSE
Low, or CD62L
Low/CFSE
Low) Pmel-1 T cells infiltrating tissues at each time point.
(B, C) Mean +/2 SEM absolute numbers (left) and CFSE phenotype percentages (right) calculated from the SSC
low Thy1.1+. gate. (B) AT of 2610
6 CD8+
Pmel-1 T cells (C) AT of 3610
5 CD8+ Pmel-1 T cells Percentages shown are representative of 2–3 independent experiments with 3 mice/timepoint.
doi:10.1371/journal.pone.0021214.g002
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e21214Figure 3. Adoptively transferred Pmel-1 T cells display lytic capability in the periphery after priming by tumor growth. A) Thy 1.1+
CD8+ Pmel-1 T cells were AT into C57B/6 mice one day prior to inoculation with 2.5610
5 B16 tumor cells in Matrigel. Lymphocytes were isolated from
TDLN, spleen and tumor on indicated days and re-stimulated for 6 hours with irradiated, gp10025–33 peptide-pulsed EL4 cells to measure IFNc recall
(n=3/group). Background IFNc production was ,1% (dashed line). (B) Six days post AT of 3610
5 naive Thy 1.1+ CD8+ Pmel-1 T cells (day 9 of tumor
growth). Congenic CD45.1 splenocyte targets, differentially labeled with CFSE and loaded with either relevant (gp100, CFSE
HIGH) or irrelevant (OVA,
CFSE
LOW) peptides were AT into recipient mice at a ,1:1 ratio. One day later, spleens were isolated and FACS analysis was preformed. Histogram
plots show CFSE levels from the CD45.1/SSC gate. Graph shows mean and SEM for specific lysis calculated using formula shown (n=3/group).
doi:10.1371/journal.pone.0021214.g003
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the mean overall displacement of OT-I T cells was over 3 times
that of Pmel-1 T cells (28 mmv s8 . 9mm) (5B,C). Comparison of
OT-I and Pmel-1 tracks showed that the trajectories of Pmel-1 T
cells were much more confined than OT-I T cells (Fig. 5A). To
quantify these differences we measured the total volume of tumor
migrated over time for Pmel-1 and OT-I T cells, as represented
by the mean distance from the central point of movement
(DCPM, see Methods). Comparison of mean DCPM showed that
the bulk of OT-I T cells, or the mode of the population
distribution, have a mean DCPM over time increased .200%
compared to the bulk of Pmel-1 T cells (1.1 mm log10 vs 0.4 mm
Log 10, Fig. 5D), correlating with the differences observed
examining individual T cell tracks. Additionally, the differences
in raw mean DCPM of the total populations were shown to be
significantly different OT-I vs Pmel-1 T cells (10.9 mm vs
7.5 mm p,0.01). Even though Pmel-1 and OT-I T cells differ in
mean velocity and mean DCPM, the cells have comparable
distribution throughout the tumor. Pmel-1 and OT-I T cells were
located 17.6 and 16.8 mm away from ‘‘non tumor regions’’, inside
the tumor mass, respectively (Sup Fig. S4C). Instantaneous
velocities and tumor location comparisons for every data point
demonstrated an equal distribution throughout the tumor for
each cell type and showed no correlation between instantaneous
velocity and tumor location for either the Pmel-1 or OT-I T cells
(Sup Fig. S4C). This shows that Pmel-1 T cells are largely in
contact with tumor cells after tumor infiltration and suggests that
there is no restriction in movement through the tumor relating to
antigen specificity.
To confirm that the differences between OT-I and Pmel-1 T
cell mobility results from antigen specificity we examined OT-I T
cell mobility in a B16 tumor which had been engineered to express
OVA (MO4-YFP). Mean velocity of OT-I T cells in MO4-YFP
tumor was comparable and not significantly different than Pmel-1
T cells (mean 1.4 mm/min vs 2.0 mm/min, Fig. 5B, Movie S6).
Although the raw mean DCPM of Pmel-1 T cells and OT-1 T
cells in MO4 tumors was different (7.5 mm vs 4.1 p,0.01), the
distribution of mean DCPM OT-I T cells in MO4 is similar to
Pmel-1 T cells as is shown in figure Fig. 5D with the modes of each
population being the same (0.4 mm Log 10). However, OT-I T
cell mean velocity and mean DCPM in OVA-expressing MO4-
YFP tumor was significantly different from OT-I T cells in
antigenically irrelevant B16-YFP, similar to what has been
described previously for OT-I T cells in antigenically relevant
and irrelevant tumors [12,13,14]. Overall, these data provide an
important example of differences between antigen-specific and
non-specific mobility in B16 tumors. Taken together, the data
imply that the slower velocity, confined mobility, and long term
interactions with tumor cells of Pmel-1 T cells is antigen
dependent.
Figure 4. Custom two-photon microscope provides advanced reflectance capture capabilities. (A) The beam from a titanium-sapphire
laser (ts) passes through a polarizing beamsplitter (pb) and on to a rotating polygonal mirror (pm) driving the fast scanning axis. The beam is relayed
to a galvanometer mirror (gm) providing the slow scanning axis. Together, the scanners generate a frame rate of 22 frames per second (fps) at
5126512 pixels. The fluorescence signal generated in the tissue is reflected towards four photomultiplier tubes (pmt) separated by dichroic filters (df)
to emitter filters for CFP, GFP, YFP, and a red marker (propidium iodide). Backscattered 910 nm light is also collected by the objective lens, retracing
the optical path and collected through the confocal detector aperture (ca) onto the avalanche photodiode (rld). Depth scanning is provided by a
piezoelectric translator (pz) that positions the objective lens (ol). A programmable XY motorized stage (xt, yt) is used to form tiled composite images.
A full detailed description is available in Sup Fig. S3. (B) (LEFT) White arrows in left image demonstrate the location of blood vessels detected in the
reflectance; insert yellow box (Right) is 3D composite image. (RIGHT) Reflectance also can detect unlabeled cells, such as red blood cells shown by
white arrows. (C) B&W panels show: Collagen fibers detected through second harmonic generation, reflectance imaging and GFP-Pmel-1 T cells.
Pseudo-color overlay (RIGHT) shows co-localization of collagen (blue), with reflectance (red), Pmel-1 T cells are shown in green.
doi:10.1371/journal.pone.0021214.g004
Intra-Tumor Imaging of Self Antigen Recognition
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e21214Discussion
Through the combination of ex-vivo and in-vivo analysis, we
have shown that the immune system is capable of generating an
anti-tumor response which is able to engage in intra-tumor
recognition of cognate self tumor antigen. This demonstrates that
ignorance of self antigen does not function as an immune escape
mechanism in this model of melanoma.
Ex-vivo analysis shows that at the peak of the anti-melanoma
effector response, melanoma specific Pmel-1 T cells are primed
into competent effector cells (shown by surface phenotype, IFNc
secretion and lytic capacity in the periphery) but are unable to
mediate tumor regression. In fact, tumor cell killing was not
detected in the regions imaged either through tumor cell
disintegration during imaging or through the use of propidium
iodide (Sup Fig. S4D). We have previously shown that adoptive
transfer of 1/3 as many Pmel-1 T cells along with combinatorial
immunotherapy results in Pmel-1 T cell dependent regression of
established tumors [18]. Thus, even though Pmel-1 T cells can
actually reject B16 tumors during therapeutic intervention, in un-
modulated conditions, Pmel-1 effector phase function appears to
be abrogated in the tumor environment. This concept is in
agreement with reports demonstrating that tumor infiltration
induces a transient, but reversible block in proximal T cell
receptor signaling in the MCA38 tumor model [5,28,29]. These
papers also demonstrate that although there is a proximal block in
signaling, TIL do in fact demonstrate initiation of the signaling
before activation of feedback inhibition loops in the TCR cascade.
Therefore, our data would suggest that although the cytolytic
ability of is inhibited inside the tumor, there are still sufficient
levels of TCR signaling to provide stop signals and intergrin
activation to the migrating Pmel-1 T cells. However, the extent of
Figure 5. Intra-tumor mobility of Pmel-1 T cells is antigen specific. 1610
5 YFP-B16 tumor cells were injected in matrigel into WT C57B/6 mice
with AT 3 days later of 3610
5 naive CD8+ CFP-Pmel-1, and 3610
5 naive GFP-OT-I T cells were AT into WT C57B/6 mice bearing 3 days old YFP-B16
tumors. 4 days later of 2.5610
4 LPS stimulated SIINFEKL loaded DCs injected into the contra-lateral footpad. (A) Representative image sequence from
the 2nd region (top panel) of a 6 region time lapse image (bottom left image). Due to high density of YFP-B16 tumor mass, images and movies are
displayed in 3D volumes instead of 2D projections to enable more accurate presentation of cell location respective to other. Likewise, reflectance
data has been removed from top images in order to better facility presentation of fluorescence imagery. Ten min and 42sec separate each frame.
Bottom; overlays of Pmel-1 (blue) and OT-I (red) T cell tracks, measured for at least 10 time points, corrected for image drift are shown for each region
of the mosaic image. Top row shows 3D XYZ orientation, bottom row shows birds eye XY view. (B–D) Comparisons of mean velocity (B), 10 step
vector length (C), mean distance from center point of movement (DCPM) (D) plotting each individual Pmel-1 and OT-I T cells tracked for at least 5
time points. Mean and SEM are shown for B and C, with a best fit curve over histogram of the population distribution show in D with modes of the
populations being 0.4 mm, 0.1 mm and 0.4 mm in Log10 for Pmel-1 T cells, OT-1 T cells and OT-1 T cells in MO4 tumor respectively. N=2 individual
experiments, with 4 mice included in the data.
doi:10.1371/journal.pone.0021214.g005
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infiltration requires further investigation.
Using intravital TPLSM imaging we examined the extent to
which tumor primed T cells were functional following infiltration
of cognate tumor. While previous reports have examined T cell
responses inside regressing tumors, these systems were limited in
their ability to study tumor induced immune dysfunction
[12,13,14]. These studies used 1) artificial foreign antigen tumor
models, 2) supra-physiologic numbers of transferred T cells and 3)
explanted tumor imaging. The use of OVA ignores the
contribution of thymic selection to the T cell repertoire’s capacity
to respond to natural tumor antigens. In addition, unrealistic T
cell precursor frequencies adversely modulate the subsequent
response to antigen [18]. Lastly, explanting the tumor dramatically
alters the in vivo tumor environment, changing conditions which
may be directly involved in the inhibition such as hypoxia, and
glucose or arginine metabolism [6,24,25]. For this reason, our
intravital methods left the subcutaneous visceral membrane intact,
preserving tumor circulation, keeping imaging conditions as close
as possible to the pre-imaging in vivo conditions of the tumor.
Combined with transfer of 50-fold fewer self tumor antigen specific
T cells, it makes this research uniquely relevant to understanding
the natural barriers to cancer immunity.
The ability to image in these conditions was made possible
through the development of a dual mode reflectance confocal and
two-photon microscope. Collection of backscattered or reflected
infrared laser light during imaging provided important internal
control data by illuminating the ‘‘black void’’ and, combined with
the video rate acquisition, makes it exceedingly easy to spatially
locate regions for imaging. Speed also permitted the collection of
multiple adjacent regions (up to 9 with 30 slices in under 2 min)
enabling acquisition of a large sample of data without extending
the time the mouse remained under anesthesia with exposed tissue.
Regardless of the method of imaging used, previous reports of
tumor imaging have laid the groundwork for our understanding of
T cell function in progressing syngeneic tumors [12,13,14]. The
differences in mean velocity, mean DCPM and track comparisons
strongly indicate that Pmel-1 mobility in the tumor is antigen
specific. This is further supported by the fact that differences in
OT-I mobility in irrelevant YFP-B16 and OVA-expressing MO4-
YFP mirror those seen for OT-I mobility in irrelevant antigen
expressing tumors (EL.4) compared to cognate antigen OVA
positive tumors (EG.7) [12,13,14]. Additionally, Pmel-1 T cell
interactions with tumor cells have a polarized nature, looking
synonymous with what is seen between CTL and target cells in-
vitro (Movie S3). More research is needed to confirm the polarity
of intra-tumor Pmel-1 T cells, however, combined with the data
presented here, it indicates that the mobility of Pmel-1 T cells
results from self antigen recognition in the tumor.
The inclusion of OT-I T cells in the experiment has also
enhanced our understanding of the mechanism of intra-tumor
immune inhibition. If Pmel-1 T cell mobility had been more
similar to that of OT-I T cells, it would have suggested that Pmel-1
T cells, due to priming or inhibition, were ignorant of intra-tumor
self antigen recognition. Moreover, had both cell types displayed a
more immobile and non-active (rounded) phenotype, we might
consider that a global inhibition generated by soluble factors
affected all T cells within the tumor microenvironment. Yet, the
evidence presented here implies that this is not the case.
A clue to how this antigen specific block may be induced comes
from examining response kinetics of the entire immune infiltrate.
At the point at which we imaged, when the number of anti-tumor
effector cells peaks as a percentage of the tumor, the number of
regulatory immune cells do as well (Fig. 1). Thus, there is a specific
enrichment of regulatory cells (Tregs, MDSC) within the tumor,
suggesting that this may be part of the mechanism involved in
suppressing intra-tumor T cell effector function. Although the
exact role these cells play, and the mechanisms involved needs to
be elucidated possible clues come from studies of CT44 tumors
expressing influenza antigen HA. In this model, tumor specific
CD8+ T cells appear to be fully primed but are inhibited in the
periphery from effector functions by antigen specific Tregs. While
there does not appear to be a block in peripheral effector functions
in our melanoma model, the intra-tumor Pmel-1 T cell mobility
phenotype is similar to interaction between T cells and HA loaded
B cell targets in the presence of antigen-specific Tregs from CT44
TDLNs [21]. However, whether or not Tregs modulate intra-
tumor Pmel-1 function in a similar manner requires further
investigation.
Understanding the exact mechanism and source of tumor
induced immune inhibition is paramount to the design of more
effective cancer immunotherapy. The intra-vital imaging tech-
niques we employed permitted us to investigate the immune
response to self antigen in a manner which could not have been
accomplished through traditional ex vivo analysis alone. Moreover,
the advances made by our microscope design can be integrated
existing platforms to study various biological questions. This
research demonstrates that antigen recognition can occur inside
the tumor based on self proteins. Therefore, we suggest that
therapeutic efforts should focus as much on determination and
neutralization of the natural barriers to an anti-tumor immune
response, as they currently do on priming it.
Supporting Information
Figure S1 Adoptively transferred Pmel-1 T cells do not
prime in the absence of tumor. A) 3610
5 Naive CFSE
labeled Thy 1.1+ CD8+ Pmel-1 T cells were AT into B16 tumor
bearing C57BL/6 mice 3, 6 or 9 day after tumor challenge.
Tumors were assessed for Pmel-1 T cell infiltration 7 and 9 days
after transfer, corresponding with day 10–12, 13–15, and 16–18
after tumor challenge for the three groups. No significant
differences were seen in the absolute number of Pmel-1 T cells
infiltrating the tumor when comparing all groups (One way anova,
tukey multiple comparison). B)_1610
6 Naive CFSE labeled Thy
1.1+ CD8+ Pmel-1 T cells were AT into naı ¨ve C57BL/6 mice.
Spleens and Lymph nodes were isolated and single cell suspensions
were prepared from 3 mice every 48 hours beginning at 24 hours
after transfer for up to 7 days. Samples were then analyzed to
determine the extent of Pmel-1 T cell infiltration and the
activation state of the infiltrating cells. (LEFT) SSC/Thy 1.1
FACS plots are representative from 7 days post transfer.
Percentages of tissue infiltrating Thy 1.1+ Pmel-1 T cells are
shown in the gate. RIGHT panels show CD44/CFSE on noted
days post transfer in Spleen (top) and Lymph node (bottom). Gates
show representative percentages of activated (CD44
High/CFSE
Low)
Pmel-1 T cells infiltrating tissues at each time point from the parent
SSC
low Thy 1.1+gate. Example is representative of 2 independent
experiments.
(PDF)
Figure S2 Schematic Blueprints for Dual mode cofocal/
two photon microscope. Complete list of abbreviations form
figure 3A: (ac) autocorrelator, (at) attenuator, (ccd) charge-coupled
device, (cl) collection lens, (ei) Epifluorescence illumination, (fds)
fluorescence detection system, (gc) group-velocity dispersion
compensator, (pl) pump laser, (qwp) quarter-wave plate, (sl)
synchronization diode laser, (sp) synchronization photodetector
(to) trinocular. As illustrated in Figure 3A, a mode locked titanium-
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10 W, diode-pumped solid-state laser (Tsunami and Millennia Xs,
Spectra-Physics), generates a beam of ,90 femtosecond, band-
width limited pulses at 80 MHz, with approximately 1 W average
power at a central wavelength of 910 nm. We used a group
velocity dispersion pre-compensator with a pair of Brewster prisms
in double-pass arrangements to introduce negative dispersion into
the pulsed beam to correct the widening of pulse width caused by
dispersive optics (1). The pulse width is measured by an
autocorrelator (Carpe, APE). Laser beam is blocked by a computer
controlled mechanical shutter (SH-10, Electro Optical Products
Corporation) to the scanner and sample when not imaging. A
rotating polygonal mirror and a galvanometric mirror form the
scanning engine of the system. A 32-facet polygonal mirror (DT-
32-394-035/LB12-5, Lincoln Laser) spins at approximately
22,000 rpm (revolutions per minute) to generate the fast-scan in
the horizontal (X) direction. The horizontal scan rate is
11.733 kHz (85.23 ms period) and an active scan time of 59.3 ms
(70%). The slower vertical (Y) scanning is achieved with a
galvanometer driven mirror (VM2000 with 9.5 mm mirror, GSI
Lumonics). When acquiring 5126512 pixel images, the frame rate
is 22 fps with a pixel dwell time of 115 ns. The polygonal mirror
may also be run at slower speeds (16,500 rpm, 11,000 rpm and
5,500 rpm) to increase pixel dwell times, if needed. The scanner is
coupled to a custom epi-illumination fluorescence microscope
based on commercial parts (Nikon). The Nikon objective lenses
(Nikon: CFI 40XW and 60XW) are mounted to the nosepiece
with a piezoelectric (PI: N-725 PIFOC) under computer control.
The user can observe the sample in widefield mode through the
eyepieces of a trinocular. To navigate on much larger sample area,
the user can move the sample horizontally with a joystick that
controls a motorized X-Y translation stage (BioPrecision 99S000,
LUDL). The X-Y stage is mounted on a vertical stage (B49
Elevating Table, Velmex) that provides manual adjustment of Z
position. During imaging, X-Y translation stage and piezoelectric
(Z-axis) are controlled by the computer to perform manual or
scripted automatic movement. After settling on the area of interest,
the user engages the scanner coupling mirror to image in the
multiphoton/confocal mode. The multi-photon fluorescence
signal generated in the sample and collected by the objective lens
is reflected towards the collection lens by a broadband, high OD,
longpass dichroic mirror at 735 nm (FF735-Di01-25636, Sem-
rock). The collected fluorescence signal is passed through an array
of dichroic filters, operating at 45 degrees, to bandpass emitter
filters and onto the photomultiplier detectors (HC-120-13,
Hamamatsu). The first beamsplitter has the center frequency of
520 nm (FF520-Di01-25636, Semrock). The pass-through light is
diverted by a secondary beamsplitter with a center frequency of
495 nm (FF495-Di01-25636, Semrock), while the reflected light is
diverted by a beamsplitter with a center frequency of 560 nm
(FF560-Di01-25636, Semrock). In this arrangement, the fluores-
cence signal is divided into four separate bands that are further
filtered by bandpass elements before reaching the photomulti-
pliers. Confocal detector module is placed at the entrance to the
scanning system. It has a polarizing beamsplitter cube aligned with
the beam in the P polarization for maximum transmission. A
broadband quarter wave retarder (AQ-100-0840, Meadowlark
Optics) is placed just before the objective lens at the far end of the
optical path. The linearly polarized laser beam passes through the
quarter wave retarder, positioned at 45 degrees to the incoming
polarization, becomes circularly polarized, traverses the objective
lens, and is focused on the sample. The light reflected back by the
sample and collected by the objective lens passes the quarter wave
retarder a second time to have a further 45 degrees phase added to
induce a half-wave retardance and a 90-degree rotation of the
linear polarization. On retracing the optical system, the polarizing
beamsplitter cube will divert the sample-reflected light in to the
confocal detector. Thus, all back-reflections from elements in the
optical path before the quarter wave plate (that do not undergo a
90 degree polarization rotation) will be transmitted by the
beamsplitter cube (onto the GVD and laser), and only reflections
from the sample (and objective lens, unfortunately), that undergo a
90 degree rotation, will be directed to the confocal detector (2).
Supplementary Figure S3 shows the functional schematic diagram
of the connections and data flow of the control and acquisition
system. We designed the timing synchronization electronics to
reduce pixel jitter caused by timing mismatch between the free-
running polygon mirror and the pixel clock of frame grabber. We
used a diode laser and photodiode pair reflected off the polygonal
mirror to generate the start of scan signal (SOS), which is
conditioned by custom circuitry to generate the pixel clock phase
matched to the rotating polygon. H-Sync and V-Sync signals that
are also triggered by SOS, along with the pixel clock, are fed into
the frame grabbers (PXI-1409, National Instruments) as the timing
signals. Frame grabbers digitize the analog signals from the
fluorescence and reflectance detectors to form the images. Thus,
because imaging acquisition of fluorescence and reflectance signals
is precisely synchronized with the free spinning polygon mirror,
pixel jitter along the scanning lines is minimized to approximate
1/60 of pixel time. The control and acquisition hardware consists
of a Windows PC workstation, DAC (Digital-Analog converter,
PXI-6713 and PXI-6070, National Instruments) and video frame
grabbers installed in the NI PXI-1000 external enclosure. Every
frame grabber can take up to 4 inputs secuentially and digitizes the
analog video signals into the images that later are retrieved by the
host PC. Our system can acquire simultaneously from 3 video
channels without dropping frames. Custom software written in
Labview controls the majority of peripheral devices (laser power,
PMT gain, Z focus, etc.) within the user interface. Captured
images are pseudo-color coded and displayed in real time. We
designed a series of imaging modes (single frame, multi-frame
acquisition, time lapse, vertical Z-stack, X-Y mosacing, and
scripted combinations of all above.) to meet various experimental
needs. Acquired images are saved as TIFF files. We have also
developed a series of software tools in Matlab (Mathworks Inc) to
batch-process the stitching together of mosaiced images, projection
of stacked images, etc. Further details of hardware and software
can be obtained from authors. 1) O. E. Martinez, J. P. Gordon,
and R. L. Fork, ‘‘Negative group-velocity dispersion using
refraction,’’ J. Opt. Soc. Am. A 1, 1003–1006 (1984) 2) Pawley
JB, Amos WB, Dixon A, Brelje TC: Simultaneous, non interfering,
collection of optimal fluorescent and backscaltered light signals on
the MRC-500/600. Proc. Microsc. Soc. Am. 51:156–157 1993.
(PDF)
Figure S3 YFP-B16 growth, immune infiltration and
Pmel-1 T cell target potential is consistent with parental
B16. (A) 2.5610
5 B16 or YFP-B16 tumor cells were suspended in
matrigel and inoculated into WT C57B/6 mice, 10 days later
tumors were isolated, weighed (left panel) and a single cell
suspension was prepared to asses for CD8+ T cell infiltration
(middle panel). Representative FACS plots are shown (right panel).
(B) Pmel-1 T cells (effectors), activated by xenogeneic human
gp100 DNA vaccination were co-cultured for 4 hours with either
YFP-B16 or its parental B16 (targets). After 4 hours, co-cultures
were labeled with CD8 and 7AAD and specific lysis of tumor cells
was calculated using the number of CD82 7AAD+/7AAD2 in
each well, normalized to tumor cells alone.
(PDF)
Intra-Tumor Imaging of Self Antigen Recognition
PLoS ONE | www.plosone.org 11 June 2011 | Volume 6 | Issue 6 | e21214Figure S4 T cells are localized in the vicinity of blood
vessels in B16 tumors and tumor cell death is not
detected in regions infiltrated by Pmel-1 T cells. 1610
5
YFP-B16 tumor cells were suspended in matrigel and inoculated
into WT C57B/6 mice, and 3 days later 3610
5 naive CD8+ GFP
or CFP Pmel-1 T cells were AT (N=4). After 10 days, mice were
used for intravital TPLSM after which tumors were excised
maintaining orientation, and noting location of site imaged
during TPLSM. Fresh frozen sections were prepared and
underwent either H&E or immuno-fluorescence staining. (A)
Representative 20X H&E staining of a day 10 YFP-B16 tumor,
insets are 40X views with black arrows pointing to positions of
leukocytes. For reference, scale bars=,100 mm for 20x, and
,50 mm for 40X (B) Two representative 20X immuno-fluores-
cence sections with CD31 (magenta) overlaid with CD8 (green)
and DAPI (blue). White arrows point to regions of concentrated
CD8 label which coincides with CD31 labeling. Approximate
scale bars are shown=100 mm for 20x, and ,50 mm for 40X (C)
Intra-tumor T cells positions were calculated by producing a high
digital threshold map of the tumor images (left) and then
comparing Volocity calculated cell centroid positions with tumor
map to determine cell location with respect to tumor or ‘‘not
tumor’’ using Matlab. Points represent intra-tumor location vs.
instantaneous speed for each cell tracked, for a single time point.
(D) 1610
5 YFP-B16 (green) tumor cells were suspended in
Matrigel and inoculated into WT C57B/6 mice with AT 3 days
later of 3610
5 naive CD8+ CFP-Pmel-1 T cells. Tumors were
imaged 7 days after CFP-Pmel-1 transfer. After imaging CFP-
Pmel-1 mobility, 1 mg/ml of propidium iodide was directly
injected into the center of the tumor (magenta) while the mouse
was maintained under intravital imaging conditions. Reflectance
(blue) is show in the left panels to demonstrate the outside edge of
the tumor. Propidium iodide staining is restricted to the regions
on the outside edge of the tumor only (center panel) and there is
no staining inside the tumor mass. As a positive control (right
panel), mice with YFP-B16 tumors were treated with chemo-
therapy (250 mg/kg of cyclophosphamide) 6 days after tumor
challenge and then imaged 4 days later. In the chemotherapy
treated example, PI staining is seen deep into the tumor mass,
staining larger nuclei in areas of faint YFP label.
(PDF)
Movie S1 GFP-Pmel-1 T cells traffic through TDLN
High endothelial venules (HEV). 30610
6 GFP-Pmel-1 T cells
were transferred into a YFP-B16 tumor bearing mouse. One hr
after transfer, TDLN was imaged at a single plane. Reflectance is
shown in blue, GFP-Pmel-1 in red, HEV are outlined. Movie is in
real time, 20fps. Blood flow and red blood cells can be seen
moving in the HEV using the reflectance channel. A GFP-Pmel-1
T cell can immediately be seen adhering to the vessel wall. After 1
second a GFP-Pmel-1 T cell, (1st white arrow) and after 12
seconds an unlabeled cell in reflectance (2nd white arrow) can be
seen rolling in the HEV.
(AVI)
Movie S2 Unlabeled cells appear as YFP-Ghosts moving
through YFP-tumor. Birds eye 3D movie of single quadrant
from a YFP-B16 tumor (green). Unlabeled YFP-Ghosts (dark voids
in the YFP signal can be seen moving throughout the tumor
during imaging. Tumor regions were considered viable if YFP-
ghosts could be seen migrating in the region imaged. 132 seconds
separate each frame.
(AVI)
Movie S3 Pmel-1 T cells engage in long term interac-
tions with YFP-B16 tumor cells. Representative composite
time-lapse movies zoomed into two regions of mosaic movie S3.
GFP-Pmel-1 in red, YFP-B16 in green, tracks are shown in blue.
Left panel and right panels are close up images of annotated cells
from the bottom left of and bottom right of movie S3, respectively.
Pmel-1 T cells can be seen engaging in long term interactions with
tumor cells (white arrows) throughout the time period of the
image. Black arrow points to a Pmel-1 T cell which engages a
tumor cell for approximately 20 min before disengaging and
moving away. One hundred and fifteen seconds separate each
frame.
(AVI)
Movie S4 OT-1 T cells infiltrate the same region of YFP-
B16 tumor and are more mobile than Pmel1-T cells.
Large view representative time-lapse image of YFP-B16 (green)
tumor 7 days post transfer of 3610
5 naive CD8+ CFP-Pmel-1 T
cells (Cyan) and CD8+ GFP-OT-1 (red) T cells. Birds eye 3D
image contains 6 adjacent regions. Seventy-seven seconds separate
each frame. Global view of tumor shows GFP-OT-1 T cells
moving faster and less confined than CFP-Pmel-1 T cells.
(AVI)
Movie S5 Non-specific OT-1 T cells do not engage in
long term interactions with B16 tumor cells. Representa-
tive time-lapse image shows close up view of the top middle region
from movie S6. YFP-B16 (green) tumor 7 days post transfer of
3610
5 naive CD8+ CFP-Pmel-1(Cyan) and CD8+ GFP-OT-1
(red) T cells. Representative T cell tracks are show in red for OT-1
T cells, and blue for Pmel-1 T cells. Density of YFP in the image
has been reduced to permit better observation of OT-1 and Pmel-
1 T cells. Seventy-seven seconds separate each frame. Arrows
(white=Pmel-1, black=OT-1) point to examples of cells which
are engaged with tumor cells at the beginning of the movie. Movie
demonstrates that non-specific GFP-OT-1 T cells do not engage in
long term interactions with tumor cells in contrast to tumor-
specific CFP-Pmel-1 T cells.
(AVI)
Movie S6 OT-1 T cells have reduced mobility and
engage in long term interactions with ova expressing
MO4-YFP tumor cells. Representative time-lapse image shows
MO4-YFP (green) tumor 7 days post transfer of 3610
5 naive
CD8+ GFP-OT-1 (red) T cells. Representative T cell tracks are
show in red. Movie demonstrates that in OVA expressing MO4-
YFP, GFP-OT-1 T cells have mobility and interact with tumor
cells similar to Pmel-1 T cells.
(AVI)
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